EPHI it's ready to moving!!! shorts will be killed !!
--------------------------------------------------------------------------------
Related Quotes
EPHI
0.710000
-0.140000
delayed 20 mins - disclaimer
Monday May 10, 10:14 am Eastern Time
Company Press Release
Electropharmacology Restructures Along Two Focus Product Areas
POMPANO BEACH, Fla.--(BUSINESS WIRE)--May 10, 1999-- Electropharmacology, Inc.'s (Gemini Health Technologies, Inc.) (OTC BB: EPHI - news) management is implementing a plan to continually update shareholders as it implements its new business - developing and commercializing proprietary biotechnology products and services.
The company recently restructured itself to develop what its management believes are two major technologies - drug delivery and drug design to address the needs in treating complex diseases such as cancer, tissue degenerative diseases and inflammation.
Electropharmacology states that its primary focus is to execute its detailed business plan of acquisitions and manage growth in order to Maximize Future Shareholder Value. By partnering with Elan Group (NYSE: ELN - news; investment transaction & corporate partnering) Electropharmacology will be continually updating its shareholder base with expansion and growth initiatives.
The two focus product areas are:
- Drug Delivery - an emerging market of over twelve billion dollars, growing at 20% + annually. Electropharmacology plans on taking ''drug delivery'' technologies into clinical testing in 1999, supporting agreements with Pharmaceutical and Biotech companies to generate licensing income in the year 2000. Additional treatments can be developed for chronic degenerative disorders such as arthritis, osteoporosis, and Alzheimer's disease. Biotech and Pharmaceutical companies involved in the drug design field are Merck (NYSE:MRK - news) Monsanto (NYSE:MTC - news), Eli Lilly (NYSE:LLY - news). Other companies involved in drug development and clinical trials are Merck (NYSE:MRK - news), American Home Products (NYSE:AHP - news), Warner Lambert (NYSE:WLA - news), and Genentech (NYSE:GNE - news).
- Drug Design - widely expected to revolutionize the entire pharmaceutical industry. The company plans to sell custom designed molecular reagents to two rapidly growing markets: medical genomics research and gene-targeted drug/diagnostic product development companies. Other similar drug design companies are: Millennium (NASDAQ:MLNM - news), and Vertex (NASDAQ:VRTX - news). According to analysts, each of these fields; tissue healing, cancer treatments and drug delivery are generating billions of dollars in revenue and are growing dramatically.
When asked to comment, Dr. A. Sen, President, said, ''We are pleased with our strategic alliance with the Elan Group, (http://www.elan.ie) as they are a leader in drug delivery technologies and products. Elan has a proven track record of developing and marketing drugs, in many areas including Parkinson's disease, epilepsy, musculoskeletal conditions, migraine headaches, arthritis, and hypertension. It is an honor to be recognized and associated with such partners.''
Shareholders can receive a complete disclosure of its restructuring in its annual 10K filing.
Electropharmacology, Inc. is a Florida based biotechnology services and products provider for both the drug design and drug delivery markets, through its patented products and corporate partners.
The foregoing Press Release contains forward looking statements, and any statements contained in this Press Release that are not statements of historical fact may be deemed to be forward looking. These statements by their nature involve substantial risks and uncertainties and actual results may differ.
--------------------------------------------------------------------------------
Contact:
Electropharmacology, Inc.
Dr. A. Sen
tel: 352/367-9088
geminihealth.com
or
Infotivity Technologies, Inc.
Greg Lohr
tel: 412\384-5535
greglohr@infotivity.com
--------------------------------------------------------------------------------
|
